ArticleEuropean radiology2018
The impact of MRI sequence on tumour staging and gross tumour volume delineation in squamous cell carcinoma of the anal canal.
Article in European radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer.International journal of radiation oncology, biology, physics · 2019Pooled it
- Innovative radiotherapy approaches.ESMO gastrointestinal oncology · 2026Review
- Diffusion-weighted magnetic resonance imaging as an early prognostic marker of chemoradiotherapy response in squamous cell carcinoma of the anus: An individual patient dataPhysics and imaging in radiation oncology · 2024Article
- PET/MRI in colorectal and anal cancers: an update.Abdominal radiology (New York) · 2023Review
- Imaging of Anal Squamous Cell Carcinoma: Survey Results and Expert Opinion from the Rectal and Anal Cancer Disease-Focused Panel of the Society of Abdominal Radiology.Abdominal radiology (New York) · 2023Review
- Hellenic society of medical oncology (HESMO) guidelines for the management of anal cancer.Updates in surgery · 2021Article
- Turbo Gradient and Spin Echo PROPELLER-Diffusion Weighted Imaging for Orbital Tumors: A Comparative Study With Readout-Segmented Echo-Planar Imaging.Frontiers in neuroscience · 2021Article
- Three-dimensional (3D) magnetic resonance volume assessment and loco-regional failure in anal cancer: early evaluation case-control study.BMC cancer · 2020Article
- Radiomics for liver tumours.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020Review
- MR guided high intensity focused ultrasound (MRgHIFU) for treating recurrent gynaecological tumours: a pilot feasibility study.The British journal of radiology · 2019Article
- MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesTo compare maximum tumour diameter (MTD) and gross tumour volume (GTV) measurements between T
methodsThe staging MRI scans of 45 SCCA patients (25 females) were assessed retrospectively by two independent radiologists (0 and 5 years' experience of anal cancer MRI). MTD and GTV were delineated on both T
resultsGTV and MTD were significantly and systematically lower on DWI versus T
conclusionsSequence selection affects SCCA measurements and T stage. DWI yields higher interobserver agreement and greater tumour delineation confidence. KEY POINTS: • MTD and GTV measurements are significantly lower on DWI than on T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.